• No results found

University of Groningen Pharmacological approaches to optimize TB treatment Zuur, Marlies

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Pharmacological approaches to optimize TB treatment Zuur, Marlies"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Pharmacological approaches to optimize TB treatment

Zuur, Marlies

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Zuur, M. (2018). Pharmacological approaches to optimize TB treatment: An individualized approach. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen

Behorende bij het proefschrift

Pharmacological approaches to optimize TB treatment;

an individualized approach

1. Dried blood spot sampling in combinatie met limited sampling is de beste manier om therapeutic drug monitoring bij tuberculose uit te voeren – dit proefschrift

2. Een hoge dosering van isoniazide en rifampicine kan het gebruik van tweedelijns tuberculosemiddelen voorkomen – dit proefschrift 3. De introductie van de dosis-afhankelijke intermediaire gevoeligheid

kan alleen kosteneffectief zijn als het slagingspercentage van behande-ling met tweedelijns tuberculosemiddelen laag is – dit proefschrift 4. One-size does not fit all, but fixed-dose combinations can – dit

proef-schrift

5. Het afnemen van een vingerprik is moeilijker dan het lijkt – dit proef-schrift

6. Zowel de farmacokinetiek als de farmacodynamiek van de behandeling van multidrug resistente tuberculose met HIV co-infectie kan op een patiëntvriendelijke manier inzichtelijk gemaakt worden met behulp van dried blood spot sampling – dit proefschrift

7. Ertapenem in combinatie met een beta-lactamase remmer is een goed alternatief voor amikacine in de behandeling van multidrug resistente tuberculose – dit proefschrift

8. The way of progress is neither swift nor easy – Marie Curie

9. Real friends are like multidrug resistant tuberculosis patients, they need special treatment.

Referenties

GERELATEERDE DOCUMENTEN

Rapid diagnosis of bacterial resistance, using molecular tests [Table 2] will enable to start the most appropriate drug regimen up front, preventing treatment with drugs that

Target attainment studies were carried out using MCE to investigate whether rifampicin, isoniazid and pyrazinamide dose increases would achieve the PK/PD target

In conclusion, this study shows that costs and QALYs could be saved with the introduction of the DDIS-TB category and subsequent treatment with high-dose isoniazid and rifampicin

Following referral from all levels of health facilities, tuberculosis (TB) diagnosis is made by sputum smear and X-ray examination, followed by starting standard treatment

Dried blood spot (DBS) sampling is a blood collection tool that uses a finger prick to obtain a blood drop on a dried blood spot card.. It can be used for therapeutic drug

DBS: dried blood spot; TDM: therapeutic drug monitoring; ARV: antiretroviral; MDR: multidrug-resistant; TB: tuberculosis; K: Potassium; Scr: Serum creatinine;

Now the variable results of in vitro studies have been explained and the activity of carbapenems in the presence of a BLaC inhibitor is established, these drugs should be

A population pharmacokinetic model and limited sampling strategy, developed using data from healthy volunteers, showed to be adequate to predict ertapenem exposure in